Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

24 October 2018

KN035, a Global Leading Subcutaneously-administered PD-L1 Antibody, Starts Late-stage Clinical Development；KN035's US Phase I clinical data was presented at the annual ESMO Congress SUZHOU, China, Oct. 23, 2018 /PRNewswire/ -- Alphamab Oncology and 3D Medicines Inc. (3D Med) announced today PD-L1 antibody KN035 has entered late stage clinical development
16 October 2018

Alphamab Oncology's HER2 bispecific antibody KN026 gained US IND approval; phase I clinical trial started in China SUZHOU, China, Oct. 16, 2018 /PRNewswire/ -- Alphamab Oncology announced that it has received US FDA's IND approval for its proprietary HER2 bispecific antibody (product code: KN026), and KN026 ...
10 October 2018

Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody KN046 enters clinical trial Alphamab Oncology announced that its proprietary humanized PD-L1 - CTLA-4 bispecific antibody (product code: KN046) program, the first of its class, has recently started phase I clinical trial in Aust...
13 April 2018

Alphamab’s Novel Her-2 Bispecific Antibody KN026 Gains IND Approval in China; CMC Validation of Its Proprietary Bispecific Platform SUZHOU, China--(BUSINESS WIRE)-Suzhou Alphamab Co., Ltd. announced today that the IND for its leading bispecific program KN026 has been approved by the CFDA, marking a significant milestone for Alpham...
30 November 2016

Global First IND for Subcutaneous Injectable anti-PD-L1 Domain Antibody Receives FDA Approval SUZHOU, China & CHENGDU, China--(BUSINESS WIRE)-3D Medicines (Sichuan) Co., Ltd. and Suzhou Alphamab Co., Ltd. announced today that the U.S. FDA has completed its review of the IND for their drug KN03...